{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T05:07:23Z","timestamp":1778994443410,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40268-022-00387-2","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T15:12:56Z","timestamp":1652454776000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation"],"prefix":"10.1007","volume":"22","author":[{"given":"Simona","family":"De Gregori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-7741","authenticated-orcid":false,"given":"Francesco","family":"Falaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Ballesio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cremonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Canta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariadelfina","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Soffiantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"387_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40121-020-00325-2","volume":"9","author":"T Morrisette","year":"2020","unstructured":"Morrisette T, Lodise TP, Scheetz MH, et al. The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse. Infect Dis Ther. 2020;9:561\u201372.","journal-title":"Infect Dis Ther"},{"key":"387_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa237.","journal-title":"Clin Infect Dis"},{"key":"387_CR3","unstructured":"Infectious Diseases Society of America (IDSA). IDSA guidelines on the treatment and management of patients with COVID-19. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/. Accessed 9 Apr 2021."},{"key":"387_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919\u201331.","journal-title":"Drug Saf"},{"key":"387_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","volume":"50","author":"JM Molina","year":"2020","unstructured":"Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.","journal-title":"Med Mal Infect"},{"key":"387_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","volume":"5","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1036\u201341. https:\/\/doi.org\/10.1001\/jamacardio.2020.1834.","journal-title":"JAMA Cardiol."},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2020.1787","volume":"5","author":"F Bessi\u00e8re","year":"2020","unstructured":"Bessi\u00e8re F, Roccia H, Delini\u00e8re A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020;5:1067\u20139.","journal-title":"JAMA Cardiol."},{"key":"387_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14182","volume":"75","author":"M Haghjoo","year":"2021","unstructured":"Haghjoo M, Golipra R, Kheirkhah J, et al. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: results of a multicenter national survey. Int J Clin Pract. 2021;75: e14182. https:\/\/doi.org\/10.1111\/ijcp.14182.","journal-title":"Int J Clin Pract"},{"key":"387_CR9","first-page":"437","volume":"297","author":"J S\u00e1nchez-Chapula","year":"2001","unstructured":"S\u00e1nchez-Chapula J, Salinas-Stefanon E, Torres-J\u00e1come J, Benavides-Haro DE, Navarro-Polanco RA. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther. 2001;297:437\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"387_CR10","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1128\/AAC.05688-11","volume":"56","author":"F Borsini","year":"2012","unstructured":"Borsini F, Crumb W, Pace S, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother. 2012;56:3261. https:\/\/doi.org\/10.1128\/AAC.05688-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/CPT.1303","volume":"105","author":"J Vicente","year":"2019","unstructured":"Vicente J, Zusterzeel R, Johannesen L, et al. Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther. 2019;105:943\u201353. https:\/\/doi.org\/10.1002\/CPT.1303.","journal-title":"Clin Pharmacol Ther"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/S12012-020-09621-2","volume":"21","author":"ML Becker","year":"2021","unstructured":"Becker ML, Snijders D, van Gemeren CW, et al. QTc prolongation in COVID-19 patients using chloroquine. Cardiovasc Toxicol. 2021;21:314\u201321. https:\/\/doi.org\/10.1007\/S12012-020-09621-2.","journal-title":"Cardiovasc Toxicol"},{"key":"387_CR13","unstructured":"Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. nature.com"},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/J.JACC.2020.04.016","volume":"75","author":"DM Roden","year":"2020","unstructured":"Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. J Am Coll Cardiol. 2020;75:2623. https:\/\/doi.org\/10.1016\/J.JACC.2020.04.016.","journal-title":"J Am Coll Cardiol"},{"key":"387_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/J.THERAP.2020.05.002","volume":"75","author":"A G\u00e9rard","year":"2020","unstructured":"G\u00e9rard A, Romani S, Fresse A, et al. \u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75:371\u20139. https:\/\/doi.org\/10.1016\/J.THERAP.2020.05.002.","journal-title":"Therapie"},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.41121","volume":"72","author":"M Petri","year":"2020","unstructured":"Petri M, Elkhalifa M, Li J, et al. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2020;72:448\u201353. https:\/\/doi.org\/10.1002\/art.41121.","journal-title":"Arthritis Rheumatol"},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/00007691-200312000-00005","volume":"25","author":"SJ Carmichael","year":"2003","unstructured":"Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671\u201381. https:\/\/doi.org\/10.1097\/00007691-200312000-00005.","journal-title":"Ther Drug Monit"},{"key":"387_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"S Tett","year":"1989","unstructured":"Tett S, Cutler D, Day R, Brown K. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03439.x.","journal-title":"Br J Clin Pharmacol"},{"key":"387_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2125.1988.tb05281.x","volume":"26","author":"S Tett","year":"1988","unstructured":"Tett S, Cutler D, Day R, Brown K. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303\u201313. https:\/\/doi.org\/10.1111\/j.1365-2125.1988.tb05281.x.","journal-title":"Br J Clin Pharmacol"},{"key":"387_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/j.1552-4604.1994.tb01986.x","volume":"34","author":"DR Brocks","year":"1994","unstructured":"Brocks DR, Skeith KJ, Johnston C, et al. Hematologic disposition of hydroxychloroquine enantiomers. J Clin Pharmacol. 1994;34:1088\u201397. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb01986.x.","journal-title":"J Clin Pharmacol"},{"key":"387_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/ard.2006.067835","volume":"66","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821\u20134. https:\/\/doi.org\/10.1136\/ard.2006.067835.","journal-title":"Ann Rheum Dis"},{"key":"387_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/acr.22837","volume":"68","author":"CC Mok","year":"2016","unstructured":"Mok CC, Penn HJ, Chan KL, et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. 2016;68:1295\u2013302. https:\/\/doi.org\/10.1002\/acr.22837.","journal-title":"Arthritis Care Res"},{"key":"387_CR23","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284\u201390. https:\/\/doi.org\/10.1002\/art.22156.","journal-title":"Arthritis Rheum"},{"key":"387_CR24","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092\u20137. https:\/\/doi.org\/10.3899\/jrheum.150379.","journal-title":"J Rheumatol"},{"key":"387_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.therap.2021.01.056","volume":"76","author":"N Zahr","year":"2021","unstructured":"Zahr N, Urien S, Llopis B, et al. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie. 2021;76:295\u2013395. https:\/\/doi.org\/10.1016\/j.therap.2021.01.056.","journal-title":"Therapie"},{"key":"387_CR26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"387_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75:11\u20138. https:\/\/doi.org\/10.1016\/0002-9343(83)91265-2.","journal-title":"Am J Med"},{"key":"387_CR28","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.hrthm.2020.06.029","volume":"17","author":"M Hooks","year":"2020","unstructured":"Hooks M, Bart B, Vardeny O, et al. Effects of hydroxychloroquine treatment on QT interval. Hear Rhythm. 2020;17:1930\u20135. https:\/\/doi.org\/10.1016\/j.hrthm.2020.06.029.","journal-title":"Hear Rhythm."},{"key":"387_CR29","doi-asserted-by":"publisher","first-page":"e008890","DOI":"10.1161\/CIRCEP.120.008890","volume":"13","author":"A Vicentini","year":"2020","unstructured":"Vicentini A, Masiello L, D\u2019Amore S, et al. QTc interval and mortality in a population of SARS-2-CoV infected patients. Circ Arrhythm Electrophysiol. 2020;13:e008890.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCEP.120.008662","volume":"13","author":"M Saleh","year":"2020","unstructured":"Saleh M, Gabriels J, Chang D, et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythmia Electrophysiol. 2020;13:496\u2013504. https:\/\/doi.org\/10.1161\/CIRCEP.120.008662.","journal-title":"Circ Arrhythmia Electrophysiol."},{"key":"387_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/CTS.13011","volume":"14","author":"A Delaunois","year":"2021","unstructured":"Delaunois A, Abernathy M, Anderson WD, et al. Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19. Clin Transl Sci. 2021;14:1133\u201346. https:\/\/doi.org\/10.1111\/CTS.13011.","journal-title":"Clin Transl Sci"},{"key":"387_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2021.174632","volume":"913","author":"U Thomet","year":"2021","unstructured":"Thomet U, Amuzescu B, Knott T, et al. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. Eur J Pharmacol. 2021;913: 714632. https:\/\/doi.org\/10.1016\/J.EJPHAR.2021.174632.","journal-title":"Eur J Pharmacol"},{"key":"387_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.15757","author":"C TeBay","year":"2021","unstructured":"TeBay C, McArthur JR, Mangala M, et al. Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. Br J Pharmacol. 2021. https:\/\/doi.org\/10.1111\/BPH.15757.","journal-title":"Br J Pharmacol"},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/TOXSCI\/KFAA194","volume":"180","author":"P Jordaan","year":"2021","unstructured":"Jordaan P, Dumotier B, Traebert M, et al. Cardiotoxic potential of hydroxychloroquine, chloroquine and azithromycin in adult human primary cardiomyocytes. Toxicol Sci. 2021;180:356\u201368. https:\/\/doi.org\/10.1093\/TOXSCI\/KFAA194.","journal-title":"Toxicol Sci"},{"key":"387_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/phar.2146","volume":"38","author":"E Tomaselli Muensterman","year":"2018","unstructured":"Tomaselli Muensterman E, Tisdale JE. Predictive analytics for identification of patients at risk for QT interval prolongation: a systematic review. Pharmacotherapy. 2018;38:813\u201321.","journal-title":"Pharmacotherapy"},{"key":"387_CR36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/heartjnl-2016-311079","volume":"103","author":"PE Lazzerini","year":"2017","unstructured":"Lazzerini PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart. 2017;103:1821\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2016-311079.","journal-title":"Heart"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00387-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T06:23:15Z","timestamp":1654323795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00387-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"6 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was funded by research\u00a0grants of Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study has been conducted in respect of the principles of the World Medical Association\u2019s Declaration of Helsinki (7th Edition, 2013). The Institutional Review Board of the Fondazione IRCCS Policlinico San Matteo (Comitato Etico della Provincia di Pavia) approved the study (Prot: 20200069934) for the patients enrolled at the post-COVID clinic (hydroxychloroquine blood concentration determinations from 26 days after treatment end, Group B).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patients whose hydroxychloroquine blood concentrations were determined during the hospital admission (Group A) gave consent to a retrospective data analysis in the current admission privacy consent form of Fondazione IRCCS Policlinico San Matteo. In the study database, single patient data were pseudo-anonymised.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors own the data and all consent\u00a0fully for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Raw data are available on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SDG, FF and MM conceived the study. SDG and FF wrote and revised the paper. AB, AF, EC, RC, US, CS and AN contributed to the data collection and analysis. AV read all the electrocardiograms and determined corrected QT intervals. ADS conducted the statistical analysis. ADS coordinated the study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}